Skip to Content

Notice

Notice of Finding of No Significant Impact and Availability of Environmental Assessment for Amendment of Materials License No. 37-30433-01, OSI Pharmaceuticals, Inc.

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

AGENCY:

Nuclear Regulatory Commission.

ACTION:

Notice of availability of environmental assessment and finding of no significant impact.

Start Further Info Start Printed Page 3956

FOR FURTHER INFORMATION CONTACT:

Betsy Ullrich, Nuclear Materials Safety Branch 2, Division of Nuclear Materials Safety, Region I, 475 Allendale Road, King of Prussia, Pennsylvania 19406, telephone (610) 337-5040, fax (610) 337-5269; or by e-mail: exu@nrc.gov.

End Further Info End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

I. Introduction

The U.S. Nuclear Regulatory Commission (NRC) is considering the issuance of a license amendment to OSI Pharmaceuticals, Inc. for Materials License No. 37-30433-01, to authorize release of its facility in Horsham, Pennsylvania for unrestricted use and has prepared an Environmental Assessment (EA) in support of this action in accordance with the requirements of 10 CFR part 51. Based on the EA, the NRC has concluded that a Finding of No Significant Impact (FONSI) is appropriate.

II. EA Summary

The purpose of the proposed action is to allow for the release of the licensee's Horsham, Pennsylvania facility for unrestricted use. OSI Pharmaceuticals, Inc. was authorized by NRC from March 9, 1998, to use radioactive materials for research and development purposes at the site. On July 10, 2003, OSI Pharmaceuticals, Inc. requested that NRC release the facility for unrestricted use. OSI Pharmaceuticals, Inc. has conducted surveys of the facility and determined that the facility meets the license termination criteria in subpart E of 10 CFR part 20.

III. Finding of No Significant Impact

The NRC staff has evaluated OSI Pharmaceuticals, Inc.'s request and the results of the surveys and has concluded that the completed action complies with the criteria in subpart E of 10 CFR part 20. The staff has prepared the EA (summarized above) in support of the proposed license amendment to terminate the license and release the facility for unrestricted use. The staff has found that the environmental impacts from the proposed action are bounded by the impacts evaluated by the “Generic Environmental Impact Statement in Support of Rulemaking on Radiological Criteria for License Termination of NRC-Licensed Facilities” (NUREG-1496). On the basis of the EA, the NRC has concluded that the environmental impacts from the proposed action are expected to be insignificant and has determined not to prepare an environmental impact statement for the proposed action.

IV. Further Information

The EA and the documents related to this proposed action, including the application for the license amendment and supporting documentation, are available for inspection at NRC's Public Electronic Reading Room at http://www.nrc.gov/​reading-rm.html (ADAMS Accession Nos. ML031970551, ML032340661 and ML040150859). These documents are also available for inspection and copying for a fee at the Region I Office, 475 Allendale Road, King of Prussia, Pennsylvania, 19406. Persons who do not have access to ADAMS, should contact the NRC PDR Reference staff by telephone at 1-800-397-4209 or (301) 415-4737, or by e-mail to exu@nrc.gov.

Start Signature

Dated in King of Prussia, Pennsylvania this 15th day of January, 2004.

For the Nuclear Regulatory Commission.

John D. Kinneman,

Chief, Nuclear Materials Safety Branch 2, Division of Nuclear Materials Safety, Region I.

End Signature End Supplemental Information

[FR Doc. E4-116 Filed 01-26-04;8:45 am]

BILLING CODE 7590-01-P